Celldex (CLDX) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Jefferies Raises Price Target on Celldex (CLDX) to $5 Following 2Q; Reiterates Hold
August 9, 2016 9:44 AM EDTJefferies reiterated a Hold rating on Celldex Therapeutics (NASDAQ: CLDX), and raised the price target to $5.00 (from $4.00), following the company's 2Q earnings report. Enrollment in the METRIC trial testing glemba in TNBC overexpressing gpNMB has been going slow. Management believes that... More
